OA12070A - Bicyclic amino acids as pharmaceutical agents. - Google Patents

Bicyclic amino acids as pharmaceutical agents. Download PDF

Info

Publication number
OA12070A
OA12070A OA1200200117A OA1200200117A OA12070A OA 12070 A OA12070 A OA 12070A OA 1200200117 A OA1200200117 A OA 1200200117A OA 1200200117 A OA1200200117 A OA 1200200117A OA 12070 A OA12070 A OA 12070A
Authority
OA
OAPI
Prior art keywords
acetic acid
aminomethyl
bicyclo
decahydro
octahydro
Prior art date
Application number
OA1200200117A
Other languages
English (en)
Inventor
Justin Stephen Bryans
David Clive Blakemore
Simon Osborne
Jean-Marie Receveur
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of OA12070A publication Critical patent/OA12070A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)

Claims (16)

  1. CO H H2n co2H i 2 -55- CLA1MS 1 2070
    1. A compound of formula
    (CH2)n I Π (CH2)n
    IV (CH2)n or a phannaceutically acceptable sait thereof, or a prodrug thereof, wherein n is an integer of from 1 to 4.
  2. 2. A compound according'to Claim 1 wherein n is an integer of from 2 to 4.
  3. 3. A compound according to Claim 1 wherein fhe compound is a compoundof Formula I.
  4. 4. A compound according to Claim 1 and selected from: add name for(1 a,6a,8P)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid;(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid; (2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid; (2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid; (3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-aceticacid; (3-Aminomethyl-bicyclo[3.2.0jhept-3-yl)-acetic acid; and(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid.
  5. 5. A compound according to Claim 1 and selected from:(la,5p)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,(la,5P)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (1 a,5P)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid, (1 a,6P)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,(la,7P)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid, -56- 1 2070 (1 a,53)(3-Aminomethyl-bicyclo[3.1,0]hex-3-yl)-acetic acid, (lcc,53)(3-Aminomethyl-bicyclo[3.2.0]hepi-3-yl)-acetic acid, $ (la,5P)(2-Ammomethyl-octahydro-pentalen-2-yl)-acetic acid, | (1 a,6p)(2-Arainomethyl-octahydro-inden-2-yl)-acetic acid, (1 a,7P)(2-Aminomethyl-decahydro-azulen-2-yI)-acetic acid, (lot,3a,5a)(3-Aniinomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid, (1 a,3a,5a)(2-Ammomethyl-octahydro-pentalen-2-yI)-acetic acid, (1 ot,6a,8a)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid, (1 oc,7a,9a)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid, (la,3p,5a)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid, (la,3p,5a)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (la,3p,5a)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid, (1 a,6cc,8P)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid, (1 a,7a,9P)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid, (( 1 R,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid, ((1 R,3 S,6R)-3-Aminomethyl-bicycîo[4.1.0]hept-3-yI)-acetic acid, ((1 S,3S,6S)-3-AminomethyI-bicyclo[4.1.0]hept-3-yl)-acetic acid, ((1 S,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid, ((lR,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid, ((lR,3S,6S)-3-Aniinomethyl-bicyclo[4.2.0]oct-3-yl)-aceticacid, ((1 S,3S,6R)-3-Aminometbyl-bicyclo[4.2.0]oct-3-yl)-acetic acid, ((1 S,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid, ((3aR,5R,7aS)-5-Aminomethyl-octahydro-inden-5-yl)-aceticacid, ((3ctR,5S,7aS)-5-Ammomethyl-octahydro-inden-5-yl)-acetic acid, ((3aS,5S,7aR)-5-Aminomethyl-octahydro-inden-5-yl)-aceticacid, ((3aS,5R,7aR)-5-Aminomethyl-octahydro-inden-5-yl)-aceticacid, ((2R,4aS,8aR)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid, » ((2S,4aS,8aR)-2-Anunomethyl-decahydro-naphthalen-2-yl)-acetic acid,((2S,4aR,8aS)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,((2R,4aR,8aS)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid, -57- 12G70 ((2R,4aS,9aR)-2-Àminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid, ((2S,4aS,9aR)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid, 5 ((2S,4aR,9aS)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)- acetic acid, • ((2R,4aR,9aS)-2-Aminometbyl-decahydro-benzocyclophepten-2«yl)-acetic acid, ((lR,3R,6S)-3-Aminomethyl-bicyclo[4.1,0]hept-3-yl)-acetic acid, 10 ((lR,3S,6S)-3-Ammomethyl-bicyclo[4.1.0]hept-3-yI)-acetic acid, ((lS,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid, ((1 S,3R,6R)-3-Aininomethyl-bicyclo[4,l .0]hept-3-yl)-acetic acid,((lR,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yi)-acetic acid, ((1R,3 S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid, 15 ((lS,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid, ((1 S,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,((3cxR,5R,7aR)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,((3aR,5S,7aR)-5-Aminoinethyl-octahydro-inden-5-yl)-aceticacid,((3aS,5S,7aS)-5-Aininomethyl-octahydro-inden-5-yi)-aceticacid, 20 ((3aS,5R,7aS)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid, ((2R,4ocR,8aR)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,((2S,4aS,8aR)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,((2S,4aR,8aS)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,((2R,4aS,8aS)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid, 25 ((2R,4aR,9aR)-2-Aminomethyl-decahydro-benzocycîophepten-2-yl)- acetic acid, ((2S,4aR,9aR)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid, ((2S,4aS,9aS)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)- 30 acetic acid, and -58- 12070 ((2R,4aS ,9aS)-2-Aminomethyî-decahydro-ben20cyclophepten-2-yl)-acetic acid.
  6. 6. A compound according to Claim 1 named (1 cx,3cx,5a)(3-Aminomethyi-bicyclo[3 2.0]hept-3-yl)-acetie acid.
  7. 7. A phannaceutical composition comprising a therapeuücally effectiveamount of a compound according to Claim 1 and a pharmaceuticallyacceptable carrier.
  8. 8. Use of a compound according to Claim 1 in the manufacture of a médicament fortreating epilepsy in a mammal.
  9. 9. Use of a compound according to Claim 1 in the manufacture of a médicament fortreating faintness attacks, hypokinesia, and cranial disorders in a mammal.
  10. 10. Use of a compound according to Claim 1 in the manufacture of a médicament fortreating neurodegenerative disorders in a mammal;
  11. 11. Use of a compound according to Claim 1 in the manufacture of a médicament fortreating dépréssion in a mammal.
  12. 12. Use of a compound according to Claim 1 in the manufacture of a médicament fortreating anxiety in a mammal;
  13. 13. Use of a compound according to Claim 1 in the manufacture of a médicament fortreating panic in a mammal.
  14. 14. Use of a compound according to Claim 1 in the manufacture of a médicament fortreating pain in a mammal.
  15. 15. Use of a compound according to Claim 1 in the manufacture of a médicament fortreating neuropathological disorders in a mammal.
  16. 16. Use of a compound according to Claim 1 in the manufacture of a médicament for treating premenstrual syndrome in a mammal. * K i I 5 1 2070 ΐ I
OA1200200117A 1999-10-20 2000-10-17 Bicyclic amino acids as pharmaceutical agents. OA12070A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20

Publications (1)

Publication Number Publication Date
OA12070A true OA12070A (en) 2003-11-10

Family

ID=22578159

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200117A OA12070A (en) 1999-10-20 2000-10-17 Bicyclic amino acids as pharmaceutical agents.

Country Status (50)

Country Link
US (2) US6689906B1 (fr)
EP (2) EP1226110B1 (fr)
JP (2) JP3632191B2 (fr)
KR (2) KR100566462B1 (fr)
CN (1) CN1165518C (fr)
AP (2) AP2002002517A0 (fr)
AR (2) AR026087A1 (fr)
AT (2) ATE293590T1 (fr)
AU (2) AU778871B2 (fr)
BG (2) BG106719A (fr)
BR (1) BR0014972B1 (fr)
CA (1) CA2386297C (fr)
CO (1) CO5280060A1 (fr)
CR (1) CR6620A (fr)
CU (1) CU23112A3 (fr)
CZ (1) CZ295960B6 (fr)
DE (2) DE60034157T2 (fr)
DO (1) DOP2000000083A (fr)
DZ (1) DZ3197A1 (fr)
EA (1) EA005206B1 (fr)
EC (1) ECSP045393A (fr)
EE (1) EE200200211A (fr)
ES (2) ES2282785T3 (fr)
GE (1) GEP20043297B (fr)
GT (2) GT200000183AA (fr)
HK (1) HK1049826B (fr)
HN (1) HN2000000224A (fr)
HR (2) HRP20020428B1 (fr)
HU (1) HUP0203325A3 (fr)
IL (3) IL149143A0 (fr)
IS (2) IS6348A (fr)
MA (1) MA26842A1 (fr)
MX (1) MXPA02003229A (fr)
MY (1) MY127678A (fr)
NO (2) NO20021780L (fr)
NZ (1) NZ517961A (fr)
OA (1) OA12070A (fr)
PA (1) PA8505201A1 (fr)
PE (1) PE20010740A1 (fr)
PL (1) PL354607A1 (fr)
PT (1) PT1226110E (fr)
SI (1) SI1226110T1 (fr)
SK (1) SK5232002A3 (fr)
SV (1) SV2001000188A (fr)
TR (2) TR200201094T2 (fr)
TW (2) TW200505824A (fr)
UA (1) UA72931C2 (fr)
WO (1) WO2001028978A1 (fr)
YU (2) YU73004A (fr)
ZA (1) ZA200202543B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
SK17922002A3 (sk) * 2000-06-26 2003-11-04 Warner-Lambert Company Obdoby gabapentínu na liečenie porúch spánku
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (fr) * 2001-01-26 2002-07-31 Warner-Lambert Company Utilisation d'acides aminés bicycliques pour la prevention et le traitement des douleurs viscérales ainsi que des maladies gastrointestinales
KR100618743B1 (ko) 2001-04-19 2006-08-31 워너-램버트 캄파니 엘엘씨 융합된 비사이클릭 또는 트리사이클릭 아미노산
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1404324B2 (fr) * 2001-06-11 2011-04-06 XenoPort, Inc. Promedicaments d'analogues de gaba, compositions et utilisations desdits promedicaments
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1469841A1 (fr) * 2002-01-31 2004-10-27 Warner-Lambert Company Ligands alpha 2 delta dans le traitement des acouphenes
AU2003246864A1 (en) * 2002-02-22 2003-09-09 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
AU2003239752A1 (en) * 2002-06-27 2004-01-19 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
MXPA05001643A (es) * 2002-08-15 2005-04-25 Pfizer Uso terapeutico de aminoacidos biciclicos y triciclicos condensados.
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
WO2004052360A1 (fr) 2002-12-11 2004-06-24 Xenoport, Inc. Promedicaments d'analogues gaba fusionnes, compositions pharmaceutiques, et utilisations correspondantes
WO2004054560A1 (fr) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Ligand alpha-2-delta pour traiter des symptomes des voies urinaires inferieures
CA2451267A1 (fr) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
PL377520A1 (pl) 2002-12-13 2006-02-06 Warner-Lambert Company Llc Pochodne pregabaliny przeznaczone do leczenia fibromialgii i innych zaburzeń
EP1663398B1 (fr) 2003-09-12 2009-11-25 Pfizer Limited Associations comprenant des ligands alpha-2-delta et des inhibiteurs du recaptage de la serotonine et de la noradrenaline
WO2006092692A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
MX2009006575A (es) 2006-12-22 2009-07-02 Recordati Ireland Ltd Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids).
MX2010003394A (es) 2007-09-28 2010-04-09 Daiichi Sankyo Co Ltd Derivado de gamma-aminoacido biciclico.
HUE031770T2 (en) 2009-03-26 2017-08-28 Daiichi Sankyo Co Ltd A method for producing a bicyclic gamma-amino acid derivative
BR112013031360B1 (pt) 2011-06-08 2022-01-25 Daiichi Sankyo Company, Limited Método para produzir um composto
HUE035366T2 (en) 2011-06-08 2018-05-02 Daiichi Sankyo Co Ltd A method for the preparation of a bicyclic compound by Claisen rearrangement
KR101944575B1 (ko) 2011-12-15 2019-04-17 다이이찌 산쿄 가부시키가이샤 부제 촉매를 사용하는 2고리형 화합물의 광학 분할 방법
HUE033397T2 (en) 2012-04-10 2017-12-28 Daiichi Sankyo Co Ltd A method for the optical separation of bicyclic compounds by an enzyme
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018166855A1 (fr) 2017-03-16 2018-09-20 Basf Se Dihydroisoxazoles à substitution hétérobicyclique
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) * 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
CU23048A3 (es) 1997-10-27 2005-06-24 Warner Lambert Co Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos

Also Published As

Publication number Publication date
KR20020040900A (ko) 2002-05-30
DE60034157T2 (de) 2007-12-13
HRP20040709A2 (en) 2004-12-31
BG106719A (bg) 2003-02-28
AU778871B2 (en) 2004-12-23
EE200200211A (et) 2003-06-16
EP1226110B1 (fr) 2005-04-20
US20040152779A1 (en) 2004-08-05
NO20043663L (no) 2002-04-16
BR0014972B1 (pt) 2011-09-06
JP3632191B2 (ja) 2005-03-23
JP2005036009A (ja) 2005-02-10
ZA200202543B (en) 2003-09-23
EP1506955B1 (fr) 2007-03-28
BG108860A (en) 2006-03-31
HK1049826B (zh) 2005-02-25
IS6348A (is) 2002-04-17
CR6620A (es) 2004-02-02
EA005206B1 (ru) 2004-12-30
HRP20020428A2 (en) 2005-02-28
YU73004A (sh) 2005-11-28
US6689906B1 (en) 2004-02-10
DZ3197A1 (fr) 2001-04-26
PE20010740A1 (es) 2001-07-27
EP1226110A1 (fr) 2002-07-31
HUP0203325A3 (en) 2003-12-29
CU23112A3 (es) 2006-02-27
EP1506955A1 (fr) 2005-02-16
DOP2000000083A (es) 2002-03-30
CO5280060A1 (es) 2003-05-30
PA8505201A1 (es) 2002-08-29
HK1049826A1 (en) 2003-05-30
IL164060A0 (en) 2005-12-18
CN1382118A (zh) 2002-11-27
ECSP045393A (es) 2004-10-23
IL149143A0 (en) 2002-11-10
EA200200293A1 (ru) 2002-10-31
GT200000183AA (es) 2005-06-17
WO2001028978A1 (fr) 2001-04-26
TR200500221T2 (tr) 2005-03-21
AR045456A2 (es) 2005-10-26
IS7497A (is) 2004-10-08
BR0014972A (pt) 2002-07-16
HN2000000224A (es) 2001-04-11
IL149143A (en) 2007-02-11
CA2386297C (fr) 2010-02-09
ES2282785T3 (es) 2007-10-16
KR20060013701A (ko) 2006-02-13
KR100566462B1 (ko) 2006-03-31
HUP0203325A2 (hu) 2003-02-28
MY127678A (en) 2006-12-29
JP3744928B2 (ja) 2006-02-15
TW200505824A (en) 2005-02-16
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
DE60034157D1 (de) 2007-05-10
ES2237464T3 (es) 2005-08-01
NO20021780D0 (no) 2002-04-16
NZ517961A (en) 2002-12-20
CA2386297A1 (fr) 2001-04-26
JP2003512348A (ja) 2003-04-02
AP2004003186A0 (en) 2004-12-31
KR100593349B1 (ko) 2006-06-26
ATE358116T1 (de) 2007-04-15
AP2002002517A0 (en) 2002-06-30
NO20021780L (no) 2002-04-16
CZ20021310A3 (cs) 2003-05-14
DE60019628D1 (de) 2005-05-25
CZ295960B6 (cs) 2005-12-14
SK5232002A3 (en) 2003-07-01
DE60019628T2 (de) 2006-01-19
CN1165518C (zh) 2004-09-08
TR200201094T2 (tr) 2002-09-23
AU2005201268A1 (en) 2005-04-21
US6835751B2 (en) 2004-12-28
HRP20020428B1 (en) 2006-02-28
ATE293590T1 (de) 2005-05-15
AU1092001A (en) 2001-04-30
AR026087A1 (es) 2002-12-26
TWI225855B (en) 2005-01-01
UA72931C2 (uk) 2005-05-16
SI1226110T1 (en) 2005-08-31
SV2001000188A (es) 2001-09-07
MA26842A1 (fr) 2004-12-20
PL354607A1 (en) 2004-01-26
MXPA02003229A (es) 2002-09-30
YU29302A (sh) 2005-06-10
PT1226110E (pt) 2005-07-29

Similar Documents

Publication Publication Date Title
CA2386297C (fr) Acides amines bicycliques utilises comme agents pharmaceutiques
US6316638B1 (en) Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
JP3756761B2 (ja) 医薬として有用な環状アミノ酸およびその誘導体
EP1180094B1 (fr) Acides amines polycycliques accoles utilises comme agents pharmaceutiques
US20050250800A1 (en) Conformationally constrained compounds as pharmaceutical agents
MXPA00009494A (en) Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel